Diseases / Eczema
Eczema
DiseaseEczema (dermatitis) refers to inflammatory skin conditions characterized by itch, redness, and rash, with symptom severity varying by subtype and chronicity. Atopic dermatitis is the most common form and often begins in childhood. Clinical burden can range from localized lesions to widespread recurrent disease.
- Trials
- 452
- Recruiting
- 57
- Completed
- 259
- With results
- 130
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | — | — | — | 1 | — | 1 | — | 2 |
| Phase 1 | 5 | — | — | 2 | 14 | 3 | 1 | — | — | — | 25 |
| Phase 1/2 | — | — | — | — | 6 | 1 | — | — | 1 | — | 8 |
| Phase 2 | 10 | — | 2 | 7 | 70 | 12 | 2 | — | 3 | — | 106 |
| Phase 2/3 | 2 | — | — | — | 2 | 1 | — | — | — | — | 5 |
| Phase 3 | 5 | 2 | 1 | 5 | 53 | 6 | 6 | — | 1 | — | 79 |
| Phase 4 | 4 | 1 | — | 1 | 19 | — | 1 | — | 3 | — | 29 |
| Not applicable | 13 | 6 | — | 2 | 68 | 10 | 4 | — | 18 | — | 121 |
| Unknown | 18 | 5 | 4 | 7 | 27 | — | 2 | 1 | 12 | 1 | 77 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Eczema | 2 | 25 | 8 | 106 | 5 | 79 | 29 | 121 | 77 | 452 |
| Dermatitis, Atopic | 1 | 21 | 5 | 88 | 5 | 66 | 25 | 66 | 47 | 324 |
| Dermatitis | — | 4 | 1 | 23 | — | 26 | 4 | 13 | 8 | 79 |
| Skin Diseases | — | 1 | 1 | 17 | 1 | 21 | — | 7 | 4 | 52 |
| Pruritus | — | 2 | — | 12 | — | 11 | 3 | 13 | 3 | 44 |
| Hypersensitivity | — | 2 | — | 5 | — | 10 | 1 | 7 | 8 | 33 |
| Psoriasis | 1 | 2 | — | 5 | — | — | 1 | 9 | 12 | 30 |
| Asthma | — | 2 | — | 3 | — | 3 | — | 6 | 12 | 26 |
| Immune System Diseases | — | — | 1 | 8 | — | 8 | — | — | 2 | 19 |
| Skin Diseases, Eczematous | — | 1 | — | 5 | 1 | 9 | — | — | 1 | 17 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Pfizer | 25 | 14 |
| 2 | Eli Lilly and Company | 22 | 20 |
| 3 | Regeneron Pharmaceuticals | 11 | 5 |
| 4 | Incyte Corporation | 10 | 6 |
| 5 | National Institute of Allergy and Infectious Diseases (NIAID) | 9 | 0 |
| 6 | Novartis Pharmaceuticals | 8 | 0 |
| 7 | University of California, San Francisco | 7 | 0 |
| 8 | Organon and Co | 6 | 5 |
| 9 | Almirall, S.A. | 5 | 3 |
| 10 | Amgen | 5 | 3 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | dupilumab | 19 |
| 2 | abrocitinib | 15 |
| 3 | lebrikizumab | 15 |
| 4 | baricitinib | 9 |
| 5 | Adrenal Cortex Hormones | 6 |
| 6 | pimecrolimus | 6 |
| 7 | Blood Specimen Collection | 4 |
| 8 | Exercise | 4 |
| 9 | gusacitinib | 4 |
| 10 | Betamethasone | 3 |
Evidence
- Results reported
- 50.2%130 of 259 completed
- Published
- 9.3%24 of 259 completed
- Primary endpoint met
- 74.1%143 of 193 analyses
- Median months to report
- 12.5
Documents disclosed
Trial profile
- Median enrollment
- 93
- Median duration
- 19.1months
- Countries
- 69
- Study sites
- 5476
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 100
- Phase 1
- 33
- Phase 1/2
- 39
- Phase 2
- 121
- Phase 2/3
- 66
- Phase 3
- 367
- Phase 4
- 37
- Not applicable
- 50
- Unknown
- 276
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | New York | United States | 70 |
| 2 | San Antonio | United States | 66 |
| 3 | Tampa | United States | 64 |
| 4 | Los Angeles | United States | 59 |
| 5 | Birmingham | United States | 55 |
| 6 | Portland | United States | 54 |
| 7 | San Diego | United States | 52 |
| 8 | Miami | United States | 51 |
| 9 | Houston | United States | 49 |
| 10 | Warsaw | Poland | 49 |
Terminations
- Terminated
- 33
- Withdrawn
- 17
- Suspended
- 1
- Stopped for recruitment
- 0.4%2 of 452 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04031469 Suspended | Suspended | Administrative | 2030-12-10 |
| NCT04214548 Withdrawn | Withdrawn | Company shifted focus | 2030-07-31 |
| NCT07187089 Withdrawn | Withdrawn | Sponsor Decision | 2028-01-05 |
| NCT05882877 Terminated | Terminated | Sponsor Decision | 2026-07-01 |
| NCT06155513 Terminated | Terminated | There has been an important change to the product formulation. | 2025-11-05 |
| NCT06219213 Terminated | Terminated | There was an important change in the product formulation | 2025-11-05 |
| NCT06469385 Terminated | Terminated | Planned safety, efficacy and proof of mechanism obtained | 2025-08-04 |
| NCT05614817 Withdrawn | Withdrawn | Sponsor Decision | 2025-07-31 |
| NCT06447506 Terminated | Terminated | Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility criterion for efficacy. No safety concerns were identified. | 2025-07-29 |
| NCT05999799 Terminated | Terminated | Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified. | 2025-07-23 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: